Expectations trend
FY2028 · fiscal year ending 2028-04-30 · fmp
PHARMACYTE BIOTECH INC (PMCB)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.38+12.03%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for PMCB yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Achieve positive free cash flow | A primary condition in PHARMACYTE BIOTECH INC's published investment case. The stated target is Free cash flow yield improves to >=0%. | Broken | Free cash flow yield remains negative beyond next 4 quarters | Valuation inputs unavailable A completed valuation measurement is required. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-04-30 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Dec 17, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making business with fragile earnings quality, rather than a proven durable compounder. The long-term thesis is in a watch state: recent performance trails its industry cohort, though the evidence says it has not freshly broken.
The evidence provides no valuation measure or explicit account of market expectations, so whether PMCB is cheap or expensive versus peers is unclear. The main visible expectation risk is fundamental: the elevated chance of another near-term earnings miss reflects its smaller size and recent pattern of misses.
Near term, execution looks uncertain, with neutral recent financial performance and a high stated risk of an earnings miss. The healthcare sector backdrop has strengthened, but a recent change in the certifying accountant and an earlier listing-rule notice add governance and listing concerns; the evidence does not establish their outcome.
The multi-year view depends in part on whether PMCB’s financial performance improves relative to its industry cohort and whether the recent pattern of earnings misses changes. In the near term, weakening jobs data could hurt cyclical names, while stronger results and guidance from sector bellwethers could sustain the healthcare tailwind; misses or lower guidance from those companies could weaken it.
Over the next 1 to 3 years, the thesis remains uncertain: sector momentum is supportive, but fragile earnings quality, recent underperformance, and elevated near-term miss risk weigh on the business case. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| PharmaCyte Biotech is advancing cell therapies for cancer and diabetes. |
| Intact |
| No meaningful clinical progress or regulatory setbacks occur |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Maintain Nasdaq listing compliance | A primary condition in PHARMACYTE BIOTECH INC's published investment case. The stated target is No further delisting notices or trading suspensions over next 12 months. | Under Pressure | Any new Nasdaq delisting notice or trading suspension issued | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.24 → $-0.24 · observed estimates
FY2028 revenue: comparable history unavailable.
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-08-02 | $-0.24 | Unavailable | 1 / 0 |
| 2026-08-03 | $-0.24 | Unavailable | 1 / 0 |
| 2026-08-04 | $-0.24 | Unavailable | 1 / 0 |
| 2026-08-05 | $-0.24 | Unavailable | 1 / 0 |
| 2026-08-06 | $-0.24 | Unavailable | 1 / 0 |
| 2026-08-07 | $-0.24 | Unavailable | 1 / 0 |
| 2026-08-08 | $-0.24 | Unavailable | 1 / 0 |
| 2026-08-09 | $-0.24 | Unavailable | 1 / 0 |
| 2026-08-10 | $-0.24 | Unavailable | 1 / 0 |
| 2026-08-12 | $-0.24 | Unavailable | 1 / 0 |
| 2026-08-13 | $-0.24 | Unavailable | 1 / 0 |
| 2026-08-14 | $-0.24 | Unavailable | 1 / 0 |
| 2026-08-15 | $-0.24 | Unavailable | 1 / 0 |
| 2026-08-16 | $-0.24 | Unavailable | 1 / 0 |
| 2026-08-17 | $-0.24 | Unavailable | 1 / 0 |
| 2026-08-18 | $-0.24 | Unavailable | 1 / 0 |
| 2026-08-19 | $-0.24 | Unavailable | 1 / 0 |
| 2026-08-20 | $-0.24 | Unavailable | 1 / 0 |
| 2026-08-21 | $-0.24 | Unavailable | 1 / 0 |
| 2026-08-22 | $-0.24 | Unavailable | 1 / 0 |
| 2026-08-23 | $-0.24 | Unavailable | 1 / 0 |
| 2026-08-24 | $-0.24 | Unavailable | 1 / 0 |
| 2026-08-25 | $-0.24 | Unavailable | 1 / 0 |
| 2026-08-26 | $-0.24 | Unavailable | 1 / 0 |
| 2026-08-27 | $-0.24 | Unavailable | 1 / 0 |
| 2026-08-28 | $-0.24 | Unavailable | 1 / 0 |
| 2026-08-29 | $-0.24 | Unavailable | 1 / 0 |
| 2026-08-30 | $-0.24 | Unavailable | 1 / 0 |
| 2026-08-31 | $-0.24 | Unavailable | 1 / 0 |
| 2026-09-01 | $-0.24 | Unavailable | 1 / 0 |
| 2026-09-02 | $-0.24 | Unavailable | 1 / 0 |
| 2026-09-03 | $-0.24 | Unavailable | 1 / 0 |
| 2026-09-04 | $-0.24 | Unavailable | 1 / 0 |
| 2026-09-05 | $-0.24 | Unavailable | 1 / 0 |
| 2026-09-06 | $-0.24 | Unavailable | 1 / 0 |
| 2026-09-07 | $-0.24 | Unavailable | 1 / 0 |
| 2026-09-08 | $-0.24 | Unavailable | 1 / 0 |
| 2026-09-09 | $-0.24 | Unavailable | 1 / 0 |
| 2026-09-10 | $-0.24 | Unavailable | 1 / 0 |
| 2026-09-11 | $-0.24 | Unavailable | 1 / 0 |
| 2026-09-12 | $-0.24 | Unavailable | 1 / 0 |
| 2026-09-13 | $-0.24 | Unavailable | 1 / 0 |
| 2026-09-14 | $-0.24 | Unavailable | 1 / 0 |
| 2026-09-15 | $-0.24 | Unavailable | 1 / 0 |
| 2026-09-16 | $-0.24 | Unavailable | 1 / 0 |
| 2026-09-17 | $-0.24 | Unavailable | 1 / 0 |
| 2026-09-18 | $-0.24 | Unavailable | 1 / 0 |
| 2026-09-19 | $-0.24 | Unavailable | 1 / 0 |
| 2026-09-20 | $-0.24 | Unavailable | 1 / 0 |
| 2026-09-21 | $-0.24 | Unavailable | 1 / 0 |
| 2026-09-22 | $-0.24 | Unavailable | 1 / 0 |
| 2026-09-23 | $-0.24 | Unavailable | 1 / 0 |
| 2026-09-24 | $-0.24 | Unavailable | 1 / 0 |
| 2026-09-25 | $-0.24 | Unavailable | 1 / 0 |
| 2026-09-26 | $-0.24 | Unavailable | 1 / 0 |
| 2026-09-27 | $-0.24 | Unavailable | 1 / 0 |
| 2026-09-28 | $-0.24 | Unavailable | 1 / 0 |
| 2026-09-29 | $-0.24 | Unavailable | 1 / 0 |
| 2026-09-30 | $-0.24 | Unavailable | 1 / 0 |
| 2026-10-01 | $-0.24 | Unavailable | 1 / 0 |
| 2026-10-02 | $-0.24 | Unavailable | 1 / 0 |
| 2026-10-03 | $-0.24 | Unavailable | 1 / 0 |
| 2026-10-04 | $-0.24 | Unavailable | 1 / 0 |
| 2026-10-05 | $-0.24 | Unavailable | 1 / 0 |
| 2026-10-06 | $-0.24 | Unavailable | 1 / 0 |
| 2026-10-07 | $-0.24 | Unavailable | 1 / 0 |
| 2026-10-08 | $-0.24 | Unavailable | 1 / 0 |
| 2026-10-09 | $-0.24 | Unavailable | 1 / 0 |
| 2026-10-10 | $-0.24 | Unavailable | 1 / 0 |
| 2026-10-11 | $-0.24 | Unavailable | 1 / 0 |
| 2026-10-12 | $-0.24 | Unavailable | 1 / 0 |
| 2026-10-13 | $-0.24 | Unavailable | 1 / 0 |
| 2026-10-14 | $-0.24 | Unavailable | 1 / 0 |
| 2026-10-15 | $-0.24 | Unavailable | 1 / 0 |
| 2026-10-16 | $-0.24 | Unavailable | 1 / 0 |
| 2026-10-17 | $-0.24 | Unavailable | 1 / 0 |
| 2026-10-18 | $-0.24 | Unavailable | 1 / 0 |
| 2026-10-19 | $-0.24 | Unavailable | 1 / 0 |
| 2026-10-20 | $-0.24 | Unavailable | 1 / 0 |
| 2026-10-21 | $-0.24 | Unavailable | 1 / 0 |
| 2026-10-22 | $-0.24 | Unavailable | 1 / 0 |
| 2026-10-23 | $-0.24 | Unavailable | 1 / 0 |
| 2026-10-24 | $-0.24 | Unavailable | 1 / 0 |
| 2026-10-25 | $-0.24 | Unavailable | 1 / 0 |
| 2026-10-26 | $-0.24 | Unavailable | 1 / 0 |
| 2026-10-27 | $-0.24 | Unavailable | 1 / 0 |
| 2026-10-28 | $-0.24 | Unavailable | 1 / 0 |
| 2026-10-29 | $-0.24 | Unavailable | 1 / 0 |
| 2026-10-30 | $-0.24 | Unavailable | 1 / 0 |
| 2026-10-31 | $-0.24 | Unavailable | 1 / 0 |
| 2026-11-01 | $-0.24 | Unavailable | 1 / 0 |
| 2026-11-02 | $-0.24 | Unavailable | 1 / 0 |
| 2026-11-03 | $-0.24 | Unavailable | 1 / 0 |
| 2026-11-04 | $-0.24 | Unavailable | 1 / 0 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Monthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.